-
Posted by
Two Blokes April 24, 2025 -
Filed in
Stock
-
13 views
Sanofi: strong Q1 performance and 2025 guidance confirmed Paris, April 24, 2025 Q1 sales growth of 9.7% at CER 1 and business EPS 2 of €1.79 Pharma launches reached sales of €0.8 billion, up 43.8%, driven by ALTUVIIIO Dupixent sales were €3.5 billion, up 20.3% Vaccines sales were €1.3 billion, up 11.4%, driven by favorable Beyfortus phasing Research and Development expenses reached €1.8 billion, up 6.9% Selling, general and administrative expenses were €2.2 billion, up 3.8% Business EPS was €1.79, up 15.7% at CER and up 17.0% reported; IFRS EPS was €1.52 Pipeline continued to deliver Six regulatory approvals across medicines in immunology, rare diseases, and oncology Recent new data from the mid-stage pipeline unlocks late-stage studies in asthma and skin diseases, broadening and deepening the scope in immunology Sustainability strategy Updated sustainability strategy focuses on access to healthcare, environmental impact, and resilience of healthcare systems. 70% of the portfolio and >75% of the pipeline target diseases that are impacted by climate and environmental challenges Capital allocation The closing of the sale of a controlling stake in Opella to CD&R is anticipated in Q23 Sanofi has agreed to acquire DR-0201, a targeted bispecific myeloid cell engager4 Guidance confirmed In 2025, sales are anticipated to grow by a mid-to-high single-digit percentage at CER5.
